Patents by Inventor Stephen Elledge

Stephen Elledge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11834653
    Abstract: Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MC class II molecules; a molecular reporter of Granzyme B (GzB) activity; and c) an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout (e.g., caspase 3 knockout). Described herein, in another aspect, is a system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: December 5, 2023
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Stephen Elledge, Tomasz Kula, Mohammad Haj Dezfulian
  • Publication number: 20200102553
    Abstract: Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MC class II molecules; a molecular reporter of Granzyme B (GzB) activity; and c) an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout (e.g., caspase 3 knockout). Described herein, in another aspect, is a system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell.
    Type: Application
    Filed: June 8, 2018
    Publication date: April 2, 2020
    Inventors: Stephen Elledge, Tomasz Kula, Mohammad Haj Dezfulian
  • Patent number: 8993318
    Abstract: The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified herein.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: March 31, 2015
    Assignees: The Brigham and Women's Hospital, Inc., The General Hospital Corporation
    Inventors: Abraham Brass, Stephen Elledge
  • Publication number: 20120331576
    Abstract: The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified herein
    Type: Application
    Filed: December 10, 2010
    Publication date: December 27, 2012
    Applicants: THE GENERAL HOSPITAL CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Abraham Brass, Stephen Elledge
  • Publication number: 20120021953
    Abstract: The present invention provides compositions, including vectors, and methods for the rapid subcloning of nucleic acid sequences in vivo and in vitro. In particular, the invention provides vectors used to contain a gene of interest that comprise a sequence-specific recombinase target site. These vectors are used to rapidly transfer the gene or genes of interest into any vector that contains a sequence-specific recombinase target site located downstream of a regulatory element so that the gene of interest may be regulated.
    Type: Application
    Filed: December 22, 2010
    Publication date: January 26, 2012
    Inventors: Stephen Elledge, Qinghua Liu
  • Publication number: 20100273859
    Abstract: Disclosed herein are methods for treating and/or preventing HIV infection in a cell. The methods involve downmodulating one or more of the HIV-dependency factors (HDFs) disclosed herein to thereby treat and/or prevent HIV infection in the cell. Downmodulating the HDFs can be by contacting the cell with an agent that downmodulates the HDF. Also disclosed herein are methods for treating and/or preventing HIV infection in a subject comprising downmodulating one or more of the HIV-dependency factors (HDFs), disclosed herein, to thereby treat and/or prevent HIV infection in the subject. The method may further comprise selecting a subject diagnosed with or at risk for HIV infection, prior to downmodulating. Downmodulating the HDFs may comprise administering an agent that downmodulates the HDF to the subject such that the agent contacts HIV host cells of the subject. The agent may inhibit HDF gene expression, protein synthesis, HDF function or HDF activity, or combinations thereof.
    Type: Application
    Filed: December 15, 2008
    Publication date: October 28, 2010
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., IMMUNE DISEASE INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Stephen Elledge, Judy Lieberman, Abraham L. Brass
  • Publication number: 20100099096
    Abstract: The present invention is directed to retroviral vectors, and libraries generated from the vectors that can be used in assessing the stability of proteins and in correlating degradation with a specific E3 ubiquitin ligase. The libraries can also be used to identify factors that alter the degradation of proteins of therapeutic value and which have potential use clinically.
    Type: Application
    Filed: February 26, 2008
    Publication date: April 22, 2010
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Stephen Elledge, Hsueh-Chi Yen
  • Publication number: 20080025958
    Abstract: This invention provides barcoded shRNA libraries and methods of using same.
    Type: Application
    Filed: November 21, 2006
    Publication date: January 31, 2008
    Inventors: Gregory Hannon, Stephen Elledge
  • Publication number: 20070292954
    Abstract: The present invention is directed methods for cloning DNA by homologous recombination. The methods can be used without a need for ligases or restriction enzymes and allow for the rapid alignment of multiple DNA fragments.
    Type: Application
    Filed: April 19, 2007
    Publication date: December 20, 2007
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventor: Stephen Elledge
  • Publication number: 20050136447
    Abstract: The present invention provides compositions, including vectors, and methods for the rapid subcloning of nucleic acid sequences in vivo and in vitro. In particular, the invention provides vectors used to contain a gene of interest that comprise a sequence-specific recombinase target site. These vectors are used to rapidly transfer the gene or genes of interest into any vector that contains a sequence-specific recombinase target site located downstream of a regulatory element so that the gene of interest may be regulated.
    Type: Application
    Filed: September 30, 2004
    Publication date: June 23, 2005
    Inventors: Stephen Elledge, Qinghua Liu